Company profile: Eleison Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology drug candidates for orphan cancers through acquisition, development, and commercialization, including Glufosfamide (glucose-linked ifosforamide mustard targeting cancer cells to reduce normal-cell toxicity), Inhaled Lipid-Complexed Cisplatin for lung diseases (prolonged effect, enhanced uptake, reduced systemic toxicity), and Dibromodulcitol requiring further safety-equivalence studies.
Products and services
- Dibromodulcitol (DBD): Drug-candidate that requires further studies to demonstrate safety equivalence to its original form, with hematologic toxicity documented as the major side effect
- Glufosfamide: Glucose-conjugated drug candidate that chemically bonds glucose to ifosforamide mustard, concentrating the active agent in cancer cells to reduce toxicity to normal cells
- Inhaled Lipid-Complexed Cisplatin (ILC): Lipid-complexed inhalation therapy for lung diseases that prolongs drug effect, enhances uptake in diseased cells, and reduces systemic toxicities
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eleison Pharmaceuticals
TomoTherapy
HQ: United States
Website
- Description: Provider of advanced radiation therapy solutions that are developed, manufactured, distributed, marketed and sold for treating a wide variety of cancers. Its ring gantry-based TomoTherapy platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TomoTherapy company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Intradigm
HQ: United States
Website
- Description: Provider of RNA interference (RNAi) therapeutics for the treatment of serious diseases, with an initial focus on oncology. The private biotechnology company leverages drug development and delivery expertise as the foundation of its RNAi platform, including a proprietary RNAi Nanoplex delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intradigm company profile →
MOMA Therapeutics
HQ: United States
Website
- Description: Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MOMA Therapeutics company profile →
Celcuity
HQ: United States
Website
- Description: Provider of oncology therapeutics and cellular analysis solutions, including gedatolisib, an investigational pan-PI3K/mTOR inhibitor for advanced breast cancer and metastatic castration-resistant prostate cancer; the CELsignia platform to measure signal transduction in live tumor cells and identify tumor drivers and potential first-in-class targeted therapies; and an Expanded Access Program for patients from closed clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celcuity company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eleison Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eleison Pharmaceuticals
2.2 - Growth funds investing in similar companies to Eleison Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eleison Pharmaceuticals
4.2 - Public trading comparable groups for Eleison Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →